Second line of therapy for gastrointestinal stromal tumors: is there a choice?
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. Currently, it is possible to carry out three consecutive lines of target therapy against metastatic GISTs: imatinib as first-line, sunitinib as second line and regorafenib as third line. The mutation status of the C-Kit gene is a p...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-06-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3050 |